Immune-based combinations show superior overall survival compared to sorafenib in advanced hepatocellular carcinoma
New data shows better survival for liver cancer patients
This systematic review and network meta-analysis of 8,138 patients evaluated immune-based combinations versus monotherapies for advanced hep…
New research highlights how specific immune-based drug combinations can improve survival rates for people with advanced liver cancer.
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
Immunotherapy Outperforms Standard Care for Advanced Liver Cancer
This Bayesian network meta-analysis of 7,301 patients with advanced hepatocellular carcinoma synthesized evidence from randomized trials. It…
A new analysis of 10 clinical trials shows that immunotherapy drugs help people with advanced liver cancer live longer than standard treatme…
Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
Sintilimab May Be Safer Lung Cancer Treatment
This retrospective cohort study evaluated 409 patients with stage IIIB-IV non-small cell lung cancer receiving PD-1 inhibitors.
One lung cancer drug may cause fewer serious side effects than others while working just as well, a real-world study suggests.
Case report describes sintilimab-associated toxic epidermal necrolysis in gastric carcinoma patient
Rare Skin Reaction Follows Successful Stomach Cancer Therapy
This case report details a patient with gastric carcinoma developing delayed-onset toxic epidermal necrolysis during neoadjuvant sintilimab …
A new case shows a common stomach cancer drug can cause dangerous skin reactions even after surgery.
SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients
Radiation Plus Immune Drugs Stops Liver Cancer Growth
This prospective Phase 2 study evaluated stereotactic body radiation therapy (SBRT) combined with continued first-line PD-1 inhibitor-based …
Combining targeted radiation with ongoing immune therapy can restart cancer control in patients whose disease was slowly spreading again.
Neoadjuvant chemotherapy plus sintilimab improved response rates versus chemotherapy alone in 61 patients with triple-negative breast cancer
Combination therapy improved response rates in a small study of triple-negative breast cancer patients
This retrospective cohort study evaluated 61 patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy at a single ce…
Adding the immunotherapy drug sintilimab to standard chemotherapy boosted response rates and slowed tumor growth in triple-negative breast c…